FDC Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
May 25, 2023 at 10:05 am EDT
Share
FDC Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 4,348.04 million compared to INR 3,410.51 million a year ago. Revenue was INR 4,418.55 million compared to INR 3,507.21 million a year ago. Net income was INR 307.13 million compared to INR 104.44 million a year ago. Basic earnings per share from continuing operations was INR 1.85 compared to INR 0.62 a year ago.
For the full year, sales was INR 17,837.5 million compared to INR 15,279.2 million a year ago. Revenue was INR 18,336.06 million compared to INR 16,040.14 million a year ago. Net income was INR 1,940.37 million compared to INR 2,164.03 million a year ago. Basic earnings per share from continuing operations was INR 11.66 compared to INR 12.81 a year ago.
FDC Limited is an India-based company, which is principally engaged in the business of pharmaceuticals. The Company manufactures and distributes its range of generics, formulations, and active pharmaceuticals at its manufacturing plants. It also manufactures oral rehydration salts (ORS) and specialized formulations. It has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. It has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
FDC LIMITED 
